Skip to main
ALMS

Alumis Inc (ALMS) Stock Forecast & Price Target

Alumis Inc (ALMS) Analyst Ratings

Based on 9 analyst ratings
Buy
Strong Buy 44%
Buy 44%
Hold 11%
Sell 0%
Strong Sell 0%

Bulls say

Alumis is a promising clinical-stage biopharmaceutical company with a strong focus on developing two TYK2 inhibitors for the treatment of Psoriasis and other immune-mediated diseases. While there is some risk in terms of market entry and pricing, the company's pipeline and potential for peak sales of $3.4 billion in 2035 demonstrate strong growth potential. In addition, the company's strategy of potentially developing a QD formulation in the future could help it better compete in a market dominated by QD options.

Bears say

Alumis is currently a clinical-stage biopharmaceutical company with a focus on developing two TYK2 inhibitors for the treatment of autoimmune and neurodegenerative diseases. However, there are significant risks to achieving their target price, including competition from other therapies and potential commercialization challenges. Additionally, the company needs to prove the efficacy and safety of their products in various indications in order to successfully enter the market and justify a premium position. However, the potential market size for their products and their current financials give them a positive outlook, and a successful phase II SLE data readout in 3Q26 could lead to further upside.

Alumis Inc (ALMS) has been analyzed by 9 analysts, with a consensus rating of Buy. 44% of analysts recommend a Strong Buy, 44% recommend Buy, 11% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Alumis Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Alumis Inc (ALMS) Forecast

Analysts have given Alumis Inc (ALMS) a Buy based on their latest research and market trends.

According to 9 analysts, Alumis Inc (ALMS) has a Buy consensus rating as of Aug 14, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $40.56, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $40.56, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Alumis Inc (ALMS)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.